assumptions

Analyzing Token Sale Models

Source Node:
Time Stamp: February 20, 2024 1:29 PM - Modified On: February 20, 2024 - Published By:
Source Cluster:
Republished By Plato

Note: I mention the names of various projects below only to compare and contrast their token sale mechanisms; this should NOT be taken as an endorsement or criticism of any specific project as a whole. It's entirely possible for any given project to be total trash as a whole and yet still have an awesome token sale model. The last few months have seen an increasing amount of innovation in token sale models. Two years ago, the space was simple: there were capped sales, which sold a fixed number of

[Mirror] A Proof of Stake Design Philosophy

Source Node:
Time Stamp: February 2, 2024 10:55 AM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

Vitalik Buterin via the Vitalik Buterin Blog This is a mirror of the post at https://medium.com/@VitalikButerin/a-proof-of-stake-design-philosophy-506585978d51 Systems like Ethereum (and Bitcoin, and NXT, and Bitshares, etc) are a fundamentally new class of cryptoeconomic organisms — decentralized, jurisdictionless entities that exist entirely in cyberspace, maintained by a combination of cryptography, economics and social consensus. They are kind of like BitTorrent, but they are also not like BitTorrent, as BitTorrent has no concept of state — a distinction that turns out to be crucially important. They are sometimes described as decentralized autonomous

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:20 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Livento Group, Inc. Announces Second Quarter Results with Revenue Growth of Over 90%, Including Significant Achievements and Updates

Source Node:
Time Stamp: August 17, 2023 3:06 PM - Modified On: August 17, 2023 - Published By:
Source Cluster:
Republished By Plato

NEW YORK, NY / August 14, 2023 / NuGene International, Inc./Livento Group, Inc. (OTC Pink:NUGN), a dynamic leader specializing in the acquisition and development of companies with disruptive business models in film, content, and technology sectors, is pleased to announce revenue growth of 91.65% for the second quarter of 2023, compared to the same period in 2022. Financial Highlights: Revenue Growth:The second quarter ending June 30, 2023, saw revenues of $431,184, up from $224,986 in 2022. For the six-month period ending June 30, 2023, revenues grew from $680,202 to $922,651, a growth of

GPOPPLUS (GPOX:US:OTC) Announces Impressive Revenue Results

Source Node:
Time Stamp: August 1, 2023 5:58 AM - Modified On: August 1, 2023 - Published By:
Source Cluster:
Republished By Plato

GPOPlus+, (GPOX:US:OTC) a leading provider and distributor of products for convenience stores and specialty retailers, gas stations, smoke shops, has recently announced an impressive surge in revenues during the fourth quarter of the year. The company reported a staggering 320% increase in its financial performance, marking a significant milestone for the organization. GPOPlus+ offers a unique technology driven direct store delivery model (“DSD”) that is creating both significant increases in revenue as well as improved unit economics with greater efficiencies yielding higher margins.  The Company has implemented this program successfully

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating